Active — Not RecruitingPhase 3

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

United States240 participantsStarted 2013-07-26

Plain-language summary

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)

Age range10 Years – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Premature discontinuation of the study drug during the Core Phase due to:
✕. Patients with known new events or concomitant medications (washout periods required prior to Visit 15) that would exclude them from the Core Phase exclusion criteria. Serological or other additional tests will not be required.

Frequency of Relapses in Patients Treated for up to 24 Months

Timeframe: 24 months

NCT IDNCT01892722

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-07-14

Results submitted2018-06-08